Understand Business Like AI

Training Example: XGEVA (Amgen) – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

XGEVA (Amgen)

(https://xgeva.com) 📸 Data Snapshot: June 20, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Serious Bone Problem Prevention | XGEVA® (denosumab) Injection (https://xgeva.com)
Title

Serious Bone Problem Prevention | XGEVA® (denosumab) Injection

Meta

Learn about XGEVA®, an injection treatment used to help prevent serious bone problems in people with multiple myeloma or bone metastases from solid tumors. See Full PI & Safety Info.

H1 Your bones matter—choose XGEVA®
H2 Is XGEVA® right for you?
H2 Ready to Start XGEVA®?
H2 Need help with your co-pay?
H2 Learn all about XGEVA®
H2 Get started with XGEVA®
H3 Since 2010, nearly 1.5 million people with cancer worldwide have been treated with XGEVA®
H6 Indication
NAV_HEADER_HEADING_REPEATED_BODY Bone Targeting Agent | XGEVA® (denosumab) Injection (https://xgeva.com/learn-about-xgeva/)
Title

Bone Targeting Agent | XGEVA® (denosumab) Injection

Meta

Learn how XGEVA® can help prevent serious bone problems in patients with bone metastases from breast, prostate, and other solid tumors or multiple myeloma. See Full PI & Safety Info.

H1 Is XGEVA® right for you? 
H2 Ask your doctor about treatment with XGEVA®.
H2 Ask your doctor about treatment with XGEVA®.
H2 What is XGEVA® (denosumab)?
H2 XGEVA® is a bone-targeting medicine used to prevent serious bone problems
H2 Talk with your doctor to see if XGEVA® may be right for you.
H2 How does XGEVA® work?
H2 Your bones are constantly changing, always breaking down and rebuilding to stay strong. Certain cells, called osteoclasts (OS•tee•oh•clasts), are designed to break down old bone, while other cells, called osteoblasts (OS•tee•oh•blasts), build bone back up.
H2 XGEVA® works to restore balance in your bones
H2 How can XGEVA® help?
H2 XGEVA® taken once every 4 weeks can help prevent serious bone problems
H2 XGEVA® provides superior protection against serious bone problems compared with ZA in people with solid tumors that spread to bone
H2 XGEVA® prevented serious bone problems 6 months longer than ZA
H2 Serious bone problems and pain
H2 Ready to find out if XGEVA® is right for you?
H2 What are the possible side effects?
H2 Here are some of the most common side effects seen in clinical trials 
H2 Learn about other serious side effects that are possible with XGEVA®
H2 Osteonecrosis of the jaw
H2 Hypocalcemia
H2 Thigh bone fractures
H2 Start the conversation
H2 Next
H2 Starting XGEVA®
H3 Click on the tabs below to learn more.
H3 Tap on the tabs below to learn more.
H3 Click on the tabs below to see how XGEVA® helped people with different types of cancer.
H3 Tap on the tabs below to see how XGEVA® helped people with different types of cancer.
H3 XGEVA® was compared with zoledronic acid (ZA), another commonly used bone-targeting medicine, in a combined analysis of three clinical studies including 5,723 people who had breast, prostate, and other types of solid tumors with bone metastases.
H3 XGEVA® prevented serious bone problems for more than 2 years
H3 XGEVA® was proven superior at preventing serious bone problems for more than 2 years
H3 XGEVA® was compared with zoledronic acid (ZA), another commonly used bone-targeting medicine, in a clinical study of 2,046 women with breast cancer and bone metastases.
H3 XGEVA® provided superior prevention from serious bone problems versus ZA
H3 XGEVA® was compared with zoledronic acid (ZA), another commonly used bone-targeting medicine, in a clinical study of 1,901 men with prostate cancer and bone metastases.
H3 XGEVA® prevented serious bone problems in people with other solid tumors
H3 XGEVA® was compared with zoledronic acid (ZA), another commonly used bone-targeting medicine, in a clinical trial of 1,597 people with solid tumors (other than breast or prostate cancer).
H3 XGEVA® helps prevent serious bone problems in people with multiple myeloma
H3 In a clinical study of 1,718 patients, XGEVA® given every 4 weeks was compared with another bone-targeting agent, zoledronic acid (ZA). The clinical study measured the time to the first serious bone problem and compared the results between XGEVA® and ZA. XGEVA® was shown to not be worse than ZA.
H3 XGEVA® given every 4 weeks was compared with ZA in women with breast cancer and bone metastases
H3 Serious bone problems cause many women with breast cancer to feel pain
H3 Time to worsening of pain was reported in studies of XGEVA® compared with ZA
H3 Women with breast cancer taking XGEVA® went 3.9 months longer before experiencing moderate to severe pain than those taking ZA
H3 These are not all the possible side effects of XGEVA®
H3 Other side effects have been reported. It is important to be aware of them and look for signs and symptoms.
H3 Click on the tabs below.
H3 Tap on the tabs below.
H3 Severe jaw bone problems called osteonecrosis (os•tee•oh•neh•CROW•sis) of the jaw (ONJ) may happen when you take XGEVA®.
H3 In studies of people with bone involvement, the rate of severe jaw problems was higher the longer they were being treated with XGEVA®.
H3 For good oral hygiene, the American Dental Association (ADA) suggests that you:
H3 Low calcium levels in the blood, known as hypocalcemia (hi•po•cal•SEE•me•ah), have been seen in people taking XGEVA®.
H3 Your doctor will test your blood calcium levels before starting you on XGEVA® and while you are in treatment.
H3 Unusual thigh bone fracture has been reported. Your thigh bone may be at risk for breaking. It may break from minimal or no impact.
H3 After stopping XGEVA®: increased risk of broken bones in the spine
H3 Be sure to review the full Important Safety Information provided below.
H4 ALL SOLID TUMORS, INCLUDING BREAST AND PROSTATE CANCER
H4 BREAST CANCER ONLY
H4 PROSTATE CANCER ONLY
H4 OTHER CANCER TYPES (SOLID TUMORS)
H4 MULTIPLE MYELOMA
H4 OSTEONECROSIS OF THE JAW
H4 HYPOCALCEMIA
H4 THIGH BONE FRACTURES
H4 FRACTURES OF THE SPINE
H6 Indication
NAV_HEADER_REPEATED Bone Metastases & Serious Bone Problems | XGEVA® (denosumab) Injection (https://xgeva.com/why-bones-matter/)
Title

Bone Metastases & Serious Bone Problems | XGEVA® (denosumab) Injection

Meta

Learn why bones may be at risk for serious bone problems after diagnosis of breast, prostate, or other types of solid tumors with bone metastases. See Full PI & Safety Info.

H1 Cancer & your bones
H2 Ask your doctor if your bones are at risk.
H2 What are serious bone problems?
H2 Have you talked with your doctor about serious bone problems?
H2 Good news!
H2 Real-life story:
H2 Bones & healthy living
H2 How can I go the extra mile with my health?
H2 Start the conversation
H2 Ready to Start XGEVA®?
H2 Next
H2 Learn about XGEVA®
H3 Read on to learn about serious bone problems and your risk of having one.
H3 When your bones are weakened by cancer, you are at risk for serious bone problems, which are:
H3 Watch out for common symptoms of a serious bone problem, including:
H3 Eat a healthy diet
H3 Get regular exercise
H6 Indication
NAV_HEADER_HEADING_REPEATED_BODY Starting XGEVA® Treatment (denosumab) Injection (https://xgeva.com/start-treatment/)
Title

Starting XGEVA® Treatment (denosumab) Injection

Meta

Learn what to expect when starting XGEVA® treatment, including dosage and injection administration. See Full PI & Safety Info.

H1 Getting started on XGEVA®—dosage and injection administration
H2 How will I get XGEVA® (denosumab)?
H2 Where will I get my shots?
H2 A convenient shot
H2 XGEVA® is not cleared from your body by the kidneys
H2 Ready to Start XGEVA®?
H2 What to expect when starting XGEVA®
H2 Before, during, and after your first shot of XGEVA®, feeling prepared can help.
H2 Before, during, and after your first shot of XGEVA®, feeling prepared can help.
H2 Ready to Start XGEVA®?
H2 Stay on track with your treatment
H2 Maintain a healthy mouth
H2 Is XGEVA® right for you?
H2 Ready to Start XGEVA®?
H3 XGEVA® is a shot (injection) given under the skin by your doctor. It does not involve infusion through your vein.
H3 Your XGEVA® injection administration will occur in either the:
H3 A shot every four weeks instead of an IV infusion. It is important to follow this XGEVA® dosing for the best chance of preventing serious bone problems.*
H3 Your doctor will need to test your blood calcium levels before you start and while you are taking XGEVA®.
H3 There’s no need to adjust your dose if you have lower kidney function. If your kidney function is not normal, your risk of seriously low blood calcium levels increases.
H3 Click on the tabs for more information.
H3 Tap on the tabs for more information.
H3 Sticking to your treatment recommendations helps give you the best chance of preventing serious bone problems
H3 Stay on track with XGEVA® by using these tips:
H3 Good dental health is important while taking XGEVA® because of the risk of osteonecrosis of the jaw, or ONJ. Follow these suggestions from the American Dental Association (ADA) to keep your mouth healthy:
H6 Indication
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://xgeva.com) Serious Bone Problem Prevention | XGEVA® (denosumab) Injection 
[H1] Your bones matter—choose XGEVA®
If you have breast, prostate, or other cancer that has spread to the bone, or multiple myeloma

[H2]
Is XGEVA® right for you?

Discuss these questions with your doctor at your next appointment

ASK YOUR DOCTOR

[IMG: Xgeva 10 year logo]

[H3] Since 2010, nearly 1.5 million people with cancer worldwide have been treated with XGEVA®
Talk with your doctor to see if XGEVA® might be right for you, too.
Start with these questions; click here.

[H2]
Ready to Start XGEVA®?

Financial support with the cost of XGEVA®, answers to treatment questions, help with insurance forms, downloadable resources—they’re all here.

LEARN MORE

[H2]
Need help with your co-pay?

The Amgen SupportPlus Co-Pay Program may help eligible patients with commercial or private insurance lower their out-of-pocket costs

LEARN MORE

[H2]
Learn all about XGEVA®

What XGEVA® is, how it works—and what it could mean for you

LEARN MORE

[H2]
Get started with XGEVA®

What to expect when you begin treatment and tips for staying on track

GO NOW
1323 chars
SUB-PAGE (https://xgeva.com/learn-about-xgeva/) Bone Targeting Agent | XGEVA® (denosumab) Injection 
[H2] XGEVA® provides superior protection against serious bone
problems
compared with ZA in people with solid tumors that spread to bone

[H3] XGEVA® was compared with zoledronic acid (ZA), another commonly used
bone-targeting medicine, in a combined analysis of three clinical studies
including 5,723 people who had breast, prostate, and other types of solid tumors
with bone metastases.

[H3] XGEVA® prevented serious bone problems for more
than 2 years

[IMG: Xgeva prevented serious bone problems for more than two years]
[IMG: Xgeva prevented serious bone problems for more than two years]

To see clinical results for your type of cancer, click the tabs below.
To see clinical results for your type of cancer, click the tabs below.

[H3] XGEVA® was proven superior at preventing serious bone problems for
more than 2 years

[H3] XGEVA® was compared with zoledronic acid (ZA), another commonly used
bone-targeting medicine, in a clinical study of 2,046 women with breast cancer
and bone metastases.

At 27 months,
[IMG: Six out of 10 patients]

[IMG: Six out of 10 patients]
taking XGEVA® had not experienced
a serious bone problem
Approximately 5 out of 10 patients on ZA had not experienced a serious bone
problem at 26.4 months.

Women treated with XGEVA®
[IMG: 18%]
[IMG: 18%]
were 18% less likely to
have
serious bone problems than with ZA

[H3] XGEVA® provided superior prevention from serious bone problems
versus ZA

[H3] XGEVA® was compared with zoledronic acid (ZA), another commonly used
bone-targeting medicine, in
a clinical study of 1,901 men with prostate cancer and bone metastases.

At 20.7 months,
[IMG: About five out of 10 patients]
[IMG: About five out of 10 patients]
taking XGEVA® had not experienced
a serious bone problem
Approximately 5 out of 10 patients taking ZA had not experienced a serious bone
problem at 17.1 months.

Men treated with XGEVA®
[IMG: 18%]
[IMG: 18%]
were 18% less likely to
have
serious bone problems than with ZA

[H3] XGEVA® prevented serious bone problems in people with other
solid tumors
[H3] XGEVA® was compared with zoledronic acid (ZA), another commonly used
bone-targeting medicine, in a clinical trial of 1,597 people with solid tumors
(other than breast or prostate cancer).
[IMG: Six months longer]
[IMG: Six months longer]
[H2] XGEVA® prevented
serious bone problems
6 months longer than ZA
Half of people had not experienced
a serious bone problem at:
21.4 months with XGEVA®
15.4 months with ZA
In the same clinical trial, but including patients
with multiple myeloma (1,776 people), XGEVA®
prevented serious bone problems.
Half of people had not experienced
a serious bone problem at:
20.5 months with XGEVA®
16.3 months with ZA
Click tab below to see results
in multiple myeloma.
Tap the tab below to see results
in multiple myeloma.

[H3] XGEVA® helps prevent serious bone problems in people
with multiple myeloma

[H3] In a clinical study of 1,718 patients, XGEVA® given every 4 weeks was
compared with another bone-targeting agent, zoledronic acid (ZA). The clinical study measured the time to the
first serious bone problem and compared the results between XGEVA®
and ZA. XGEVA® was
shown to not be worse than ZA.

[IMG: Nearly 23 months of prevention]
[IMG: Nearly 23 months of prevention]
Half of people taking XGEVA® went at least 22.8
months without experiencing a serious bone problem and half
of people taking ZA
went at least 24 months
3695 chars
SUB-PAGE · THIN (https://xgeva.com/why-bones-matter/) Bone Metastases & Serious Bone Problems | XGEVA® (denosumab) Injection 
[H2]
Good news!

There are bone-targeting medicines specifically designed to help prevent serious
bone problems before they happen.
Read on to learn more about the risk to your bones or click here to see how XGEVA® can help.
230 chars
SUB-PAGE (https://xgeva.com/start-treatment/) Starting XGEVA® Treatment (denosumab) Injection 
BEFORE YOUR SHOT

DURING YOUR SHOT

AFTER YOUR SHOT

[IMG: Milk carton]
[IMG: Milk carton]
Calcium level check
Your doctor will test your blood calcium levels, which must be regular in order to start treatment. Your doctor will correct calcium levels if they are too low.
Learn why blood calcium levels are important here.
[IMG: Pregnancy test]
[IMG: Pregnancy test]
Pregnancy test
Your doctor will check if you are pregnant before starting XGEVA®. Women should use highly effective birth control when taking XGEVA®. Birth control should be taken for at least 5 months after your last dose of XGEVA®.
Tell your doctor if you are pregnant, are planning a pregnancy, think you are pregnant, or are breastfeeding.
[IMG: Tooth]
[IMG: Tooth]
Dental evaluation
Inform your oncologist of any dental work or if you’re having tooth pain. In clinical studies, osteonecrosis of the jaw (ONJ) was reported in some people taking XGEVA®, which can be serious. Learn more about ONJ here.
It’s important to visit your dentist as often as they recommend. Let your dentist know that you are taking XGEVA®.

[IMG: T-shirt]
[IMG: T-shirt]
What to wear
When choosing what to wear to your appointment, opt for comfortable, loose-fitting clothes. This can make it easier for you, as well as the healthcare team member giving the shot.
[IMG: Injection]
[IMG: Injection]
The shot
Your doctor will choose where to give the shot. It is given under the skin and does not involve an infusion through the vein.
The area will first be sterilized with rubbing alcohol. After the shot, this area will be sterilized again and covered with some cotton and a bandage.

[IMG: Calendar]
[IMG: Calendar]
Set up routine appointments
Talk to your doctor in advance about setting up an appointment for once every 4 weeks. This will help you to get the most benefit from XGEVA®.
If you have missed a dose, it is important to talk to your doctor about getting back on track with XGEVA®. Find more tips for staying on track—scroll down!
[IMG: Take XGEVA® as prescribed]
[IMG: Take XGEVA® as prescribed]
Take XGEVA® as prescribed
Even if you don’t have symptoms, it is important to be consistent with your shots to give yourself the best chance of getting the kind of results seen in clinical studies.
To see how XGEVA® worked in clinical studies, click here.
[IMG: calcium and vitamin D supplements pill bottle]
[IMG: calcium and vitamin D supplements pill bottle]
Take calcium and vitamin D supplements for extra prevention
Continue taking these supplements at the dose prescribed by your doctor to help prevent low calcium levels in the blood.
2680 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
5Review mentions (all pages)
8External proof links (all pages)
PageReviewsProof links
/ (home) 1 2
/learn-about-xgeva/ 2 2
/why-bones-matter/ 1 2
/start-treatment/ 1 2
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema 
[
    {
        "@context": "http://schema.org",
        "@type": "MedicalWebPage",
        "audience": [
            {
                "@type": "MedicalAudience",
                "audiencetype": "Patient",
                "healthCondition": [
                    {
                        "@type": "MedicalCondition",
                        "primaryPrevention": "Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors"
                    }
                ]
            }
        ]
    },
    {
        "@context": "http://schema.org",
        "@type": "Drug",
        "isProprietary": "true",
        "name": "XGEVA",
        "activeIngredient": "denosumab",
        "url": "https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fwww.xgeva.com%2f&c=E,1,jsZFN7uVziGuW_6LKLuGWt7uFCc11h1R7tnl9p2Fym6_PMwn47JeAIxbVzxN3wR1Nbgh83nDWhtXmeartKlElTsAmu9B8Ach0NLG1yVfsqqn&typo=1",
        "prescribingInfo": "https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Xgeva/xgeva_pi.pdf",
        "description": "Discover XGEVA®, an injection treatment used to help prevent serious bone problems in people with multiple myeloma or bone metastases. See Full PI & Safety Info.",
        "dosageForm": "Injection",
        "administrationRoute": "injection",
        "drugUnit": "120mg/1.7 mL vial",
        "manufacturer": "AMGEN"
    },
    {
        "@context": "http://schema.org",
        "@type": "MedicalIndication",
        "name": "Indication",
        "description": "XGEVA® is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors."
    }
]
/learn-about-xgeva/ 
[
    {
        "@context": "http://schema.org",
        "@type": "MedicalWebPage",
        "audience": [
            {
                "@type": "MedicalAudience",
                "audiencetype": "Patient",
                "healthCondition": [
                    {
                        "@type": "MedicalCondition",
                        "name": "Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors",
                        "primaryPrevention": "Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors"
                    }
                ]
            }
        ]
    },
    {
        "@context": "http://schema.org",
        "@type": "TherapeuticProcedure",
        "adverseOutcome": [
            "In people with bone metastases from breast, prostate, and other solid tumors, some of the most common side effects seen in clinical trials: tiredness/weakness, low phosphate levels in your blood, nausea. The most common serious side effect was shortness of breath.",
            "In people with multiple myeloma, some of the most common side effects seen in clinical trials: diarrhea, nausea, low red blood cells, low blood platelets and calcium levels, back pain, swelling of the lower legs or hands, upper respiratory tract infection, rash, headache. The most common serious side effect was pneumonia."
        ]
    },
    {
        "@context": "http://schema.org",
        "@type": "MedicalTherapy",
        "seriousAdverseOutcome": "Osteonecrosis of the jaw (ONJ) is a serious adverse reaction reported in the XGEVA® clinical trials"
    },
    {
        "@context": "http://schema.org",
        "@type": "Drug",
        "isProprietary": "true",
        "name": "XGEVA",
        "activeIngredient": "denosumab",
        "url": "https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fwww.xgeva.com%2flearn-about-xgeva&c=E,1,3zEcs8ReXHnLCrRXYnOa8VU2s1x5uf3KGQGBHscEd52ureXpOIqeC5K72HQzLrxVM4QykqGw783Mmsk4IVMDuge0aQzkSJImZiqQKpPa_dJP1SdK0w,,&typo=1",
        "prescribingInfo": "https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Xgeva/xgeva_pi.pdf",
        "description": "Learn how XGEVA® can help to prevent serious bone problems in patients with multiple myeloma or from solid tumors. See Full PI & Safety Info.",
        "dosageForm": "Injection",
        "administrationRoute": "injection",
        "drugUnit": "120mg/1.7 mL vial",
        "manufacturer": "AMGEN",
        "mechanismOfAction": [
            "XGEVA® works by blocking the signals to the cells that break down bone",
            "By slowing down the overactive bone breakdown cells, XGEVA® lowers the risk of serious bone problems"
        ]
    },
    {
        "@context": "http://schema.org",
        "@type": "MedicalIndication",
        "name": "Indication",
        "description": [
            "XGEVA, also called denosumab, is prescribed for people with bone metastases from breast, prostate, and other solid tumors (cancer) and for people with multiple myeloma.",
            "XGEVA is not chemotherapy or other treatment for your cancer.",
            "XGEVA is also not Prolia (denosumab), which is used to treat different medical conditions.",
            "Do not take XGEVA if you are currently taking Prolia."
        ]
    }
]
/why-bones-matter/ 
[
    {
        "@context": "http://schema.org",
        "@type": "MedicalWebPage",
        "audience": [
            {
                "@type": "MedicalAudience",
                "audiencetype": "Patient",
                "healthCondition": [
                    {
                        "@type": "MedicalCondition",
                        "primaryPrevention": "Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors"
                    }
                ]
            }
        ]
    },
    {
        "@context": "http://schema.org",
        "@type": "Drug",
        "isProprietary": "true",
        "name": "XGEVA",
        "activeIngredient": "denosumab",
        "url": "https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fwww.xgeva.com%2fwhy-bones-matter&c=E,1,AatY9WyftBoZ3Iq8bCFoyhlyNmSidn2hEbQc61wntgSKGL3fmpBj9E0epEcUMe2h5PLyhbibtwhnyrYUGyfCKOOMjYmq0pOctcKzs_KvZMoOEc67ESoR&typo=1",
        "prescribingInfo": "https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Xgeva/xgeva_pi.pdf",
        "description": "RLearn how certain types of cancer can weaken bones, the associated symptoms and risk, and how preventative treatments can help. See Full PI & Safety Info.",
        "dosageForm": "Injection",
        "administrationRoute": "injection",
        "drugUnit": "120mg/1.7 mL vial",
        "manufacturer": "AMGEN",
        "mechanismOfAction": [
            "XGEVA® works by blocking the signals to the cells that break down bone",
            "By slowing down the overactive bone breakdown cells, XGEVA® lowers the risk of serious bone problems"
        ]
    },
    {
        "@context": "http://schema.org",
        "@type": "MedicalIndication",
        "name": "Indication",
        "description": "XGEVA® is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors."
    }
]
/start-treatment/ 
[
    {
        "@context": "http://schema.org",
        "@type": "MedicalWebPage",
        "audience": [
            {
                "@type": "MedicalAudience",
                "audiencetype": "Patient",
                "healthCondition": [
                    {
                        "@type": "MedicalCondition",
                        "primaryPrevention": "Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors"
                    }
                ]
            }
        ]
    },
    {
        "@context": "http://schema.org",
        "@type": "Drug",
        "isProprietary": "true",
        "name": "XGEVA",
        "activeIngredient": "denosumab",
        "url": "https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fwww.xgeva.com%2fstart-treatment&c=E,1,rTMRMQa8qa2r5hn_C3jMB9tUtO1UlsAdKz0j1mUyowIJ5O4QdgIPNUmgAA4cdscyFyZCQ39wh0Da6kDkFR3JuV44PGfIolvhWwqwW7DDXes,&typo=1",
        "prescribingInfo": "https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Xgeva/xgeva_pi.pdf",
        "description": "Find XGEVA® injection administration information, dosing schedule, and what to expect when starting treatment. See Full PI & Safety Info.",
        "dosageForm": "Injection",
        "doseSchedule": "Every four weeks",
        "administrationRoute": "injection",
        "drugUnit": "120mg/1.7 mL vial",
        "manufacturer": "AMGEN",
        "mechanismOfAction": [
            "XGEVA® works by blocking the signals to the cells that break down bone",
            "By slowing down the overactive bone breakdown cells, XGEVA® lowers the risk of serious bone problems"
        ]
    },
    {
        "@context": "http://schema.org",
        "@type": "MedicalIndication",
        "name": "Indication",
        "description": "XGEVA® is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors."
    }
]

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence 0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof 0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint 0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority 0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score 0 / 100
💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS

Based on 784 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: XGEVA (Amgen) (xgeva.com)

https://xgeva.com 📍 Industry: Medical Devices, Pharma & Biotech
14 BS / 100

This is a benchmark site for pharmaceutical substance, trading marketing ‘magic’ for rigorous clinical metrics. It contains almost no bullshit, functioning as a high-fidelity data bridge between the manufacturer and the patient.

Info Density Power-words vs. Substance ratio.
6
20% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
0
0% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
2
10% BS
Commodity Fingerprint Detection of industry clichés/templates.
5
33% BS
Identity & Authority Expert verifiability & Schema depth.
1
7% BS

Consolidate the repeated H2 headings on the ‘Learn’ page to improve technical structure. Remove the ‘Good news!’ placeholder marketing text on the ‘Why Bones Matter’ page and replace it with more specific skeletal risk data. Ensure the Schema sameAs links include direct entries to ClinicalTrials.gov registrations for the three primary studies cited.

The site perfectly matches the Pharma & Biotech industry, utilizing heavy regulation-driven content such as Prescribing Information (PI), specific active ingredients (denosumab), and clinical trial data comparisons.

“The score of 14 is driven primarily by the high information density and absence of semantic drift. Minor points were only accrued for template repetition and the use of standard pharma industry cliches ('Ready to Start', 'Good News').”

Verified Analysis Date: June 20, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution

This training module utilizes a snapshot of public data from XGEVA (Amgen), captured on June 20, 2026, to demonstrate how machine logic evaluates different types of business narratives.

Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.

Notice to XGEVA (Amgen): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.

Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.

To all users: You are encouraged to visit the live site at https://xgeva.com to view the most current version of its content and learn from the source what this company is about and what it offers.